Double Dip: Doctors Paid to Advise, Promote Drug Companies That Fund Their Research
Pharmaceutical companies pay for the clinical trials that Dr. Yoav Golan conducts on antibiotics at Tufts Medical Center. They also pay him tens of thousands of dollars a year to give speeches and advice on behalf of their drugs.
If Golan worked at some teaching hospitals, he would be barred or severely restricted from accepting both research funding and personal payments for promotional speaking or consulting from drug makers. These hospitals fear the money could influence clinical findings or at least create the appearance of a conflict of interest.
Yet Tufts and many other academic medical centers allow doctors to accept overlapping payments — and some doctors still take them.
A ProPublica analysis shows that more than 1,300 practitioners nationwide received both research money and speaking or consulting fees from the same drug maker in 2012. All told, they received more than $90 million in research grants — plus nearly $13 million for speaking engagements and another $4 million for consulting.
Critics say doctors who conduct a clinical trial while accepting personal payments from the company sponsoring the study can feel beholden to the drug maker.
“The pharmaceutical company has a paramount stake in a favorable outcome. The [research] grant recipient has a stake in a favorable outcome and the honorarium recipient or consultant has yet another stake in the outcome,” said David Rothman, director of the Center for Medicine as a Profession at Columbia University. “It’s not only my lab. It’s my mortgage.”
ProPublica used its Dollars for Docs database, which tracks payments to practitioners by 15 drug companies, to conduct the review. The analysis covered the nine companies that disclosed payments in this form.
Golan, an infectious disease specialist, was the only doctor who received speaking, consulting, and research payments from three companies in 2012. Pfizer, Merck, and Forest Labs gave Tufts $51,000 for his research that year, in addition to paying him $125,000 to speak about their drugs and $13,000 for consulting.
Pharmaceutical companies’ payments for promotional speaking and consulting appear to have decreased in recent years as transparency measures advanced.
One Doctor’s Overlapping Relationships
Dr. Yoav Golan, an infectious disease specialist at Tufts Medical Center, received speaking, consulting, and research payments from three companies in 2012, the only physician in ProPublica’s Dollars for Docs database that met those criteria. Some ethicists question doctors’ abilities to stay impartial when receiving both research and promotional payments from pharmaceutical companies.
| Company | Research | Consulting | Speaking | Total |
|---|---|---|---|---|
| Pfizer | $9,062 | $2,250 | $27,500 | $38,812 |
| Merck | $12,050 | $5,000 | $43,740 | $60,790 |
| Forest Labs | $30,360 | $6,050 | $53,300 | $89,710 |
Total personal payments for speaking and consulting: $137,840
Pharmaceutical companies’ payments for promotional speaking and consulting appear to have decreased in recent years as blockbuster drugs have lost patent protection and the push for transparency has advanced.
Beginning this fall, all drug companies will have to publicly disclose payments they made to doctors under the Physician Payment Sunshine Act.